Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Assessment of Minimal Residual Disease in Standard-Risk AML.
Hills RK, Ivey A, Grimwade D; UK National Cancer Research Institute (NCRI) AML Working Group. Hills RK, et al. Among authors: ivey a. N Engl J Med. 2016 Aug 11;375(6):e9. doi: 10.1056/NEJMc1603847. N Engl J Med. 2016. PMID: 27509124 Free article. No abstract available.
NUP98-NSD1 fusion in association with FLT3-ITD mutation identifies a prognostically relevant subgroup of pediatric acute myeloid leukemia patients suitable for monitoring by real time quantitative PCR.
Akiki S, Dyer SA, Grimwade D, Ivey A, Abou-Zeid N, Borrow J, Jeffries S, Caddick J, Newell H, Begum S, Tawana K, Mason J, Velangi M, Griffiths M. Akiki S, et al. Among authors: ivey a. Genes Chromosomes Cancer. 2013 Nov;52(11):1053-64. doi: 10.1002/gcc.22100. Epub 2013 Sep 2. Genes Chromosomes Cancer. 2013. PMID: 23999921
Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.
Lin WY, Fordham SE, Hungate E, Sunter NJ, Elstob C, Xu Y, Park C, Quante A, Strauch K, Gieger C, Skol A, Rahman T, Sucheston-Campbell L, Wang J, Hahn T, Clay-Gilmour AI, Jones GL, Marr HJ, Jackson GH, Menne T, Collin M, Ivey A, Hills RK, Burnett AK, Russell NH, Fitzgibbon J, Larson RA, Le Beau MM, Stock W, Heidenreich O, Alharbi A, Allsup DJ, Houlston RS, Norden J, Dickinson AM, Douglas E, Lendrem C, Daly AK, Palm L, Piechocki K, Jeffries S, Bornhäuser M, Röllig C, Altmann H, Ruhnke L, Kunadt D, Wagenführ L, Cordell HJ, Darlay R, Andersen MK, Fontana MC, Martinelli G, Marconi G, Sanz MA, Cervera J, Gómez-Seguí I, Cluzeau T, Moreilhon C, Raynaud S, Sill H, Voso MT, Lo-Coco F, Dombret H, Cheok M, Preudhomme C, Gale RE, Linch D, Gaal-Wesinger J, Masszi A, Nowak D, Hofmann WK, Gilkes A, Porkka K, Milosevic Feenstra JD, Kralovics R, Grimwade D, Meggendorfer M, Haferlach T, Krizsán S, Bödör C, Stölzel F, Onel K, Allan JM. Lin WY, et al. Among authors: ivey a. Nat Commun. 2022 Jan 4;13(1):2. doi: 10.1038/s41467-021-27679-6. Nat Commun. 2022. PMID: 34983928 Free PMC article. No abstract available.
Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.
Moujalled DM, Pomilio G, Ghiurau C, Ivey A, Salmon J, Rijal S, Macraild S, Zhang L, Teh TC, Tiong IS, Lan P, Chanrion M, Claperon A, Rocchetti F, Zichi A, Kraus-Berthier L, Wang Y, Halilovic E, Morris E, Colland F, Segal D, Huang D, Roberts AW, Maragno AL, Lessene G, Geneste O, Wei AH. Moujalled DM, et al. Among authors: ivey a. Leukemia. 2019 Apr;33(4):905-917. doi: 10.1038/s41375-018-0261-3. Epub 2018 Sep 10. Leukemia. 2019. PMID: 30214012 Free PMC article.
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.
DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, Thijssen R, Pomilio G, Ivey A, Salmon JM, Glytsou C, Fleming SA, Zhang Q, Ma H, Patel KP, Kornblau SM, Xu Z, Chua CC, Chen X, Blombery P, Flensburg C, Cummings N, Aifantis I, Kantarjian H, Huang DCS, Roberts AW, Majewski IJ, Konopleva M, Wei AH. DiNardo CD, et al. Among authors: ivey a. Blood. 2020 Mar 12;135(11):791-803. doi: 10.1182/blood.2019003988. Blood. 2020. PMID: 31932844 Free PMC article.
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.
Tiong IS, Dillon R, Ivey A, Teh TC, Nguyen P, Cummings N, Taussig DC, Latif AL, Potter NE, Runglall M, Russell NH, Raj K, Schwarer AP, Fong CY, Grigg AP, Wei AH. Tiong IS, et al. Among authors: ivey a. Br J Haematol. 2021 Mar;192(6):1026-1030. doi: 10.1111/bjh.16722. Epub 2020 May 26. Br J Haematol. 2021. PMID: 32458446 Free PMC article.
94 results